AcelRx Pharmaceuticals Performance
| ACRXDelisted Stock | USD 1.01 0.01 1.00% |
The firm shows a Beta (market volatility) of 0.06, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AcelRx Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding AcelRx Pharmaceuticals is expected to be smaller as well. AcelRx Pharmaceuticals right now shows a risk of 0.0%. Please confirm AcelRx Pharmaceuticals accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and jensen alpha , to decide if AcelRx Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AcelRx Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, AcelRx Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 12.7 M |
AcelRx |
AcelRx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 101.00 in AcelRx Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of 0.00 from holding AcelRx Pharmaceuticals or generate 0.0% return on investment over 90 days. AcelRx Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than AcelRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AcelRx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AcelRx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AcelRx Pharmaceuticals, and traders can use it to determine the average amount a AcelRx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ACRX |
Based on monthly moving average AcelRx Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AcelRx Pharmaceuticals by adding AcelRx Pharmaceuticals to a well-diversified portfolio.
AcelRx Pharmaceuticals Fundamentals Growth
AcelRx Stock prices reflect investors' perceptions of the future prospects and financial health of AcelRx Pharmaceuticals, and AcelRx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AcelRx Stock performance.
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (28.28) % | |||
| Current Valuation | 3.25 M | |||
| Shares Outstanding | 16.95 M | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 0.74 X | |||
| Price To Sales | 36.65 X | |||
| Revenue | 1.77 M | |||
| EBITDA | (30.18 M) | |||
| Cash And Equivalents | 22.92 M | |||
| Cash Per Share | 3.11 X | |||
| Total Debt | 10.42 M | |||
| Debt To Equity | 0.43 % | |||
| Book Value Per Share | 1.08 X | |||
| Cash Flow From Operations | (28.33 M) | |||
| Earnings Per Share | (2.75) X | |||
| Total Asset | 47.49 M | |||
| Retained Earnings | (425.83 M) | |||
| Current Asset | 118.95 M | |||
| Current Liabilities | 12.78 M | |||
About AcelRx Pharmaceuticals Performance
Evaluating AcelRx Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if AcelRx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AcelRx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California. Acelrx Pharmaceutica operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 43 people.Things to note about AcelRx Pharmaceuticals performance evaluation
Checking the ongoing alerts about AcelRx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AcelRx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AcelRx Pharmaceuticals is now traded under the symbol TLPH. Please update your portfolios or report it if you believe this is an error. Report It! | |
| AcelRx Pharmaceuticals is not yet fully synchronised with the market data | |
| AcelRx Pharmaceuticals has some characteristics of a very speculative penny stock | |
| AcelRx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| AcelRx Pharmaceuticals currently holds about 22.92 M in cash with (28.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing AcelRx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AcelRx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining AcelRx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AcelRx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AcelRx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AcelRx Pharmaceuticals' stock. These opinions can provide insight into AcelRx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |